We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

1 hedge funds and large institutions have $1K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% less funds holding

Funds holding: 151 (-14)

100% less capital invested

Capital invested by funds: $456K → $1K (-$455K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 14

Holders
1
Holders Change
-14
Holders Change %
-93.33%
% of All Funds
0.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BTI
1
Blue Trust Inc
Georgia
$1K
JC
2
JBF Capital
Colorado
-$286K -295,000 Closed
GS
3
GTS Securities
New York
-$48.6K -50,100 Closed
VF
4
Virtu Financial
New York
-$42K -43,558 Closed
Geode Capital Management
5
Geode Capital Management
Massachusetts
-$40.2K -41,449 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
-$22.4K -23,060 Closed
TRCT
7
Tower Research Capital (TRC)
New York
-$9.92K -10,224 Closed
BlackRock
8
BlackRock
New York
-$4.65K -4,790 Closed
SPIA
9
Steward Partners Investment Advisory
New York
-$688 -709 Closed
Wells Fargo
10
Wells Fargo
California
-$150 -154 Closed
Osaic Holdings
11
Osaic Holdings
Arizona
-$42 -43 Closed
JWA
12
JFS Wealth Advisors
Pennsylvania
-$22 -22 Closed
Fidelity Investments
13
Fidelity Investments
Massachusetts
-$13 -13 Closed
Northwestern Mutual Wealth Management
14
Northwestern Mutual Wealth Management
Wisconsin
-$11 -11 Closed

FRTX Hedge Fund Activity: Q4 2023 in Review

1 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2023, worth a combined $1K — down 100% from $456K a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of FRTX and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was JBF Capital, exiting entirely with an estimated $286K sold.

  • 1 institutional investor held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2023, down from 15 in Q3 2023.
  • Funds reported $1K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of -14 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2023 was JBF Capital, an estimated $286K sold.

Based on aggregated 13F filings for Q4 2023.